NAVEEN PEMMARAJU to Antibodies, Monoclonal
This is a "connection" page, showing publications NAVEEN PEMMARAJU has written about Antibodies, Monoclonal.
Connection Strength
0.270
-
CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123. Leuk Res. 2024 04; 139:107479.
Score: 0.096
-
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. Am J Hematol. 2020 12; 95(12):1553-1561.
Score: 0.075
-
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018 11 15; 132(20):2115-2124.
Score: 0.065
-
A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma. 2022 09; 63(9):2161-2170.
Score: 0.021
-
Update on the biology and treatment options for hairy cell leukemia. Curr Treat Options Oncol. 2014 Jun; 15(2):187-209.
Score: 0.012